Show simple item record

dc.contributor.authorKishi, Yasuhiro
dc.contributor.authorKondo, Takaaki
dc.contributor.authorXiao, Sheng
dc.contributor.authorYosef, Nir
dc.contributor.authorGaublomme, Jellert
dc.contributor.authorWu, Chuan
dc.contributor.authorWang, Chao
dc.contributor.authorChihara, Norio
dc.contributor.authorRegev, Aviv
dc.contributor.authorJoller, Nicole
dc.contributor.authorKuchroo, Vijay K.
dc.date.accessioned2017-05-02T17:41:05Z
dc.date.available2017-05-02T17:41:05Z
dc.date.issued2016-09
dc.date.submitted2015-07
dc.identifier.issn0022-1007
dc.identifier.issn1540-9538
dc.identifier.urihttp://hdl.handle.net/1721.1/108596
dc.description.abstractTh17 cells are key players in defense against pathogens and maintaining tissue homeostasis, but also act as critical drivers of autoimmune diseases. Based on single-cell RNA-seq profiling of pathogenic versus nonpathogenic Th17 cells, we identified protein C receptor (PROCR) as a cell surface molecule expressed in covariance with the regulatory module of Th17 cells. Although PROCR expression in T cells was controlled by the cooperative action of the Th17 lineage-specific transcription factors RORγt, IRF4, and STAT3, PROCR negatively regulated Th17 differentiation. CD4+ T cells from PROCR low expressor mutant mice readily differentiated into Th17 cells, whereas addition of the PROCR ligand, activated protein C, inhibited Th17 differentiation in vitro. In addition, PROCR acted as a negative regulator of Th17 pathogenicity in that it down-regulated expression of several pathogenic signature genes, including IL-1 and IL-23 receptors. Furthermore, T cell–specific deficiency of PROCR resulted in the exacerbation of experimental autoimmune encephalomyelitis (EAE) and higher frequencies of Th17 cell in vivo, indicating that PROCR also inhibits pathogenicity of Th17 cells in vivo. PROCR thus does not globally inhibit Th17 responses but could be targeted to selectively inhibit proinflammatory Th17 cells.en_US
dc.language.isoen_US
dc.publisherRockefeller University Press, Theen_US
dc.relation.isversionofhttp://dx.doi.org/10.1084/jem.20151118en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alike 3.0 Unported licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/en_US
dc.sourceRockefeller University Pressen_US
dc.titleProtein C receptor (PROCR) is a negative regulator of Th17 pathogenicityen_US
dc.typeArticleen_US
dc.identifier.citationKishi, Yasuhiro; Kondo, Takaaki; Xiao, Sheng; Yosef, Nir; Gaublomme, Jellert; Wu, Chuan; Wang, Chao, et al. “Protein C Receptor (PROCR) Is a Negative Regulator of Th17 Pathogenicity.” The Journal of Experimental Medicine 213, no. 11 (September 2016): 2489–2501. © 2016 Kishi et al.en_US
dc.contributor.departmentBroad Institute of MIT and Harvarden_US
dc.contributor.mitauthorRegev, Aviv
dc.relation.journalJournal of Experimental Medicineen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsKishi, Yasuhiro; Kondo, Takaaki; Xiao, Sheng; Yosef, Nir; Gaublomme, Jellert; Wu, Chuan; Wang, Chao; Chihara, Norio; Regev, Aviv; Joller, Nicole; Kuchroo, Vijay K.en_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0001-8567-2049
mit.licensePUBLISHER_CCen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record